Published in Maedica (Buchar) on December 01, 2014
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
A specific antidote for dabigatran: functional and structural characterization. Blood (2013) 2.77
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83
Dabigatran etexilate: a new oral thrombin inhibitor. Circulation (2011) 1.66
Gene therapy and cardiomyocyte transplant in heart failure. Maedica (Buchar) (2014) 0.75